Accession Number:



Targeting CDK4/6 in HER2-Positive Breast Cancer Brain Metastases

Descriptive Note:

Technical Report,01 Sep 2018,31 Aug 2019

Corporate Author:

Dana-Farber Cancer Institute Boston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The purpose of this project is to use patient-derived xenograft PDX models and genetically-engineered mouse models GEMMs of HER2 breast cancer brain metastases BCBM to test novel CDK46-based combination therapies for activity against HER2 BCBM. By using anti-CDK46 drugs with other targeted therapies we will be able test the potential synergy of drug combinations against HER2 BCBM. Due to pending approval of involving human subjects, we do not have any activities to report on using patient derived xenograft PDX models. However, we have made a considerable progress in mouse tumor cells and syngeneic mouse models of BCBM. Our positive preliminary results from mouse models laid the foundation for further developing effective therapeutic strategies against specific subtypes of breast cancer brain metastases, which is important for deliver pre-clinical information to guide the rational design of promising clinical trials.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: